ProShare Advisors
GLUE icon

ProShare Advisors’s Monte Rosa Therapeutics GLUE Stock Holding History

ProShare Advisors’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$302K Buy
12,462
+279
+2% +$5.27K ﹤0.01% 1412
2026
Q1 		$200K Buy
12,183
+809
+7% +$15.5K ﹤0.01% 1580
2025
Q4 		$178K Buy
11,374
+1,199
+12% +$16.2K ﹤0.01% 1753
2025
Q3 		$75.4K Sell
10,175
-1,686
-14% -$8.93K ﹤0.01% 1884
2025
Q2 		$53.5K Buy
11,861
+149
+1% +$665 ﹤0.01% 1983
2025
Q1 		$54.3K Sell
11,712
-2,829
-19% -$17.3K ﹤0.01% 1944
2024
Q4 		$101K Buy
+14,541
New +$109K ﹤0.01% 2072
2022
Q2 		– Sell
-10,230
Closed -$144K – 1926
2022
Q1 		$144K Buy
+10,230
New +$142K ﹤0.01% 1963

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ProShare Advisors's GLUE Position: Q2 2026 in Review

ProShare Advisors increased its Monte Rosa Therapeutics (GLUE) stake by 2.3% in Q2 2026, buying an estimated $5.27K and bringing the position to 12,462 shares worth $302K. The position accounts for ﹤0.01% of the portfolio, ranked #1412.

ProShare Advisors first reported a position in GLUE in Q1 2022 and has held it in 8 quarters since. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • ProShare Advisors held 12,462 shares of Monte Rosa Therapeutics worth $302K as of Q2 2026.
  • ProShare Advisors bought 279 Monte Rosa Therapeutics shares in Q2 2026, an estimated $5.27K.
  • Monte Rosa Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1412 holding.
  • ProShare Advisors first reported a position in Monte Rosa Therapeutics in Q1 2022 and has held it in 8 quarters since.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.